Lipid‐lowering efficacy and safety of alirocumab in patients with or without diabetes: <scp>A</scp> sub‐analysis of <scp>ODYSSEY COMBO II</scp>

Abstract

Over a 104-week double-blind study period, alirocumab provided consistently greater LDL-C reductions than ezetimibe, with similar LDL-C results in patients with or without DM. Safety of alirocumab was similar regardless of baseline DM status.